Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp Alfa Combined With Chemoradiotherapy in Esophageal Squamous Cell Cancer
NCT07769866Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Sep 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Open-label, single-arm trial of retlirafusp alfa in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Renji Hospital. Primary endpoint: Progression-Free Survival rate at 1 year. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07769866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07769866.